Keratin 20 (KRT20) ELISA Kits

Human Keratin 20 (KRT20) interaction partners

1. Increased cytokeratin 20 messenger RNA expression is associated with Micrometastasis and recurrence in Gastric Carcinoma.

2. combination of KRT5 and KRT20 allowed identification of patients with a very poor prognosis (KRT20/KRT5(-), 5-year DSS 0%, p < 0.0001). In silico analysis of the independent MDACC cohorts revealed congruent results (5-year DSS for KRT20 low vs. high: 84% vs. 40%, p = 0.042).

3. Carcinoid-like/labyrinthine pattern of cell arrangement in vimentin/cytokeratin 20 expressing sebaceous neoplasms may represent a morphological phenotype of sebaceous mantles.

4. In our cohort of specimens with equivocal urothelial atypia, very few patients without a prior diagnosis of bladder cancer progressed to diagnostic cancer (1 of 22), suggesting that CK20 and p53 staining results should be interpreted with caution in de novo atypia.

5. results demonstrate the diagnostic value of urinary cytology and confirm CK 20 as an adjunct marker for the diagnosis of urothelial carcinoma.

6. findings of our study imply that sequential staining of CK20 and E-cadherin prevents false-positive classification of BCC. Furthermore, our study demonstrated that p40 exhibits the same staining pattern in BCC, TE, and TB

7. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively.

8. results demonstrated upregulation of fibroblast growth factor receptor 1 and CK20 expressions in cancer bladder tissues

9. K20 expression was detected in 6 of 75 patients with triple-negative carcinoma

10. Circulating tumor cell CK20 and survivin expression may effectively predict overall survival in metastic colorectal cancer patients receiving chemotherapy.

11. During postoperative follow-up, serum negative CK20 patients had significantly higher 3-year survival rates than serum positive CK20 patients.

12. Patients with any EGFR, CK19, CK20 or survinin positivity in their peripheral blood obtain less benefit from radiotherapy.

13. Case Report: Merkel cell carcinma that initially demonstrated cytokeratin 20 positivity but lost expression in subsequent brain metastases.

14. Our data show that inclusion of CK20 as a biomarker efficiently improves the detection of CTCs in colorectal cancer patients

15. The present study confirmed that CK14, but not CK20 or CK7, is expressed in urothelial carcinoma with squamous differentiation and squamous cell carcinoma of the urinary bladder.

16. Immunostaining of CDX2 and CK20 provides beneficial information if considering whether to perform an endoscopic papillectomy (EP).

17. High cytokeratin 20 expression is associated with invasive histological phenotype in poorly differentiated colorectal adenocarcinoma.

18. Its association with clinical stage indicates that CK20 might have prognostic value as a marker for detection of circulating CRC cells.

19. The CDX2/CK20 phenotype defines a distinct subgroup of colorectal cancers with microsatellite instability and poor differentiation

20. Data show that lower survival (OS) and disease-free survival (DFS) rates were significantly associated with guanylate cyclase C (GCC) and CK20 mRNA levels.

Mouse (Murine) Keratin 20 (KRT20) interaction partners

1. K20 Ser(13) is a highly dynamic protein kinase C-related phosphorylation site that is induced during apoptosis and tissue injury